Enabling new models of care: pursuing pharma’s partnership potential
There is a huge, ongoing shift in how health and wellness is approached in the UK, and the changes will have important implications for NHS-industry partnerships.
Transformative change is coming to the NHS and is set to radically alter how the UK’s health service cares for people at a population level.
The NHS Long Term Plan signposted this change, with its emphasis on preventative health, and the forthcoming expansion of the Integrated Care Systems programme continues this direction of travel on a path towards the long-cherished hope of joining up health and social care.
As new approaches to healthcare attainment take hold there will be some degree of uncertainty among pharmaceutical companies about where they fit into the new structures and the holistic care they seek to provide.
But they’re not the only stakeholders working to map out how to enable new models of care and what their role should be.